{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:19:43Z","timestamp":1790713183995,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejso.2021.08.024","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T16:10:25Z","timestamp":1630167025000},"page":"188-196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cost-effectiveness analysis of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with gastric cancer and peritoneal metastasis"],"prefix":"10.1016","volume":"48","author":[{"given":"Mehdi","family":"Javanbakht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0321-4250","authenticated-orcid":false,"given":"Atefeh","family":"Mashayekhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Branagan-Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"K\u00f6nigsrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-6237","authenticated-orcid":false,"given":"Marc A.","family":"Reymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Yaghoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejso.2021.08.024_bib1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198544","article-title":"Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: a population-based outcomes study","volume":"13","author":"Choi","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ejso.2021.08.024_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919846402","article-title":"Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C\/D) in patients with gastric cancer and peritoneal metastasis: a phase II study","volume":"11","author":"Struller","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejso.2021.08.024_bib3","unstructured":"overview.pdf [Internet]. [cited 2019 Aug 16]. Available from: https:\/\/www.nice.org.uk\/guidance\/GID-IPG10117\/documents\/overview."},{"key":"10.1016\/j.ejso.2021.08.024_bib4","unstructured":"Palliative management for people with oesophageal and gastric cancer - NICE Pathways [Internet]. [cited 2019 Aug 16]. Available from: https:\/\/pathways.nice.org.uk\/pathways\/oesophageal-and-gastric-cancer\/palliative-management-for-people-with-oesophageal-and-gastric-cancer."},{"issue":"24","key":"10.1016\/j.ejso.2021.08.024_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006884","article-title":"Third-line chemotherapy in advanced gastric cancer: a systematic review and meta-analysis","volume":"96","author":"Zheng","year":"2017","journal-title":"Medicine (Baltim)"},{"issue":"3","key":"10.1016\/j.ejso.2021.08.024_bib6","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.soc.2018.02.006","article-title":"Evolving treatment strategies and outcomes in advanced gastric cancer with peritoneal metastasis","volume":"27","author":"Dahdaleh","year":"2018","journal-title":"Surg Oncol Clin N Am"},{"issue":"7","key":"10.1016\/j.ejso.2021.08.024_bib7","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","article-title":"Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications","volume":"20","author":"Alyami","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2021.08.024_bib8","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.ejso.2020.05.007","article-title":"Standardizing training for pressurized intraperitoneal aerosol chemotherapy","volume":"46","author":"Alyami","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2021.08.024_bib9","unstructured":"1 Recommendations | Pressurised intraperitoneal aerosol chemotherapy for peritoneal carcinomatosis | Guidance | NICE [Internet]. NICE; [cited 2021 Jul 22]. Available from: https:\/\/www.nice.org.uk\/guidance\/IPG681\/chapter\/1-Recommendations."},{"key":"10.1016\/j.ejso.2021.08.024_bib10","unstructured":"guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781.pdf [Internet]. [cited 2019 Aug 16]. Available from: https:\/\/www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781."},{"issue":"1","key":"10.1016\/j.ejso.2021.08.024_bib11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/1471082X13497642","article-title":"Modelling of overall survival by an association between progression-free and post-progression survival using a conditional distribution","volume":"14","author":"Belkacemi","year":"2014","journal-title":"Stat Model"},{"key":"10.1016\/j.ejso.2021.08.024_bib12","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.ejso.2018.10.281","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) combining with standard systemic chemotherapy in primary and recurrent gastric cancer (GC) with peritoneal carcinomatosis (PC): results of 214 procedures in 94 patients from case-control study","volume":"45","author":"Khomyakov","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2021.08.024_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1515\/pp-2016-0017","article-title":"Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and Doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2)","volume":"1","author":"Khomyakov","year":"2016","journal-title":"Pleura Peritoneum"},{"issue":"1","key":"10.1016\/j.ejso.2021.08.024_bib14","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1186\/s12885-019-5720-3","article-title":"Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study","volume":"19","author":"Arai","year":"2019","journal-title":"BMC Canc"},{"issue":"11","key":"10.1016\/j.ejso.2021.08.024_bib15","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9911","key":"10.1016\/j.ejso.2021.08.024_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2021.08.024_bib17","unstructured":"Improved curve fits to summary survival data: application to economic evaluation of health technologies | BMC Medical Research Methodology | Full Text [Internet]. [cited 2019 Aug 23]. Available from: https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/1471-2288-11-139."},{"key":"10.1016\/j.ejso.2021.08.024_bib18","unstructured":"Common Terminology criteria for adverse events (CTCAE) | protocol development | CTEP [internet]. [cited 2019 Aug 26]. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm."},{"issue":"4","key":"10.1016\/j.ejso.2021.08.024_bib19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/annonc\/mdv625","article-title":"Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Al-Batran","year":"2016","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2021.08.024_bib20","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s40273-017-0528-y","article-title":"Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy: an evidence review group perspective of a NICE Single technology appraisal","volume":"35","author":"B\u00fcy\u00fckkaramikli","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.ejso.2021.08.024_bib21","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1477-7525-6-84","article-title":"Health state utilities for non small cell lung cancer","volume":"6","author":"Nafees","year":"2008","journal-title":"Health Qual Life Outcome"},{"issue":"5","key":"10.1016\/j.ejso.2021.08.024_bib22","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1185\/03007991003712258","article-title":"Elicitation of health state utilities in metastatic renal cell carcinoma","volume":"26","author":"Swinburn","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejso.2021.08.024_bib23","author":"Paracha"},{"issue":"2","key":"10.1016\/j.ejso.2021.08.024_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40273-017-0580-7","article-title":"Impact of adverse events on health utility and health-related quality of life in patients receiving first-line chemotherapy for metastatic breast cancer: results from the SELECT BC study","volume":"36","author":"Hagiwara","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.ejso.2021.08.024_bib25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1477-7525-8-50","article-title":"Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study","volume":"8","author":"Beusterien","year":"2010","journal-title":"Health Qual Life Outcome"},{"key":"10.1016\/j.ejso.2021.08.024_bib26","unstructured":"NHS reference costs 2015 to 2016 [Internet]. GOV.UK. [cited 2019 Aug 28]. Available from: https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2015-to-2016."},{"key":"10.1016\/j.ejso.2021.08.024_bib27","unstructured":"BNF is only available in the UK [Internet]. NICE. [cited 2019 Oct 2]. Available from: https:\/\/www.nice.org.uk\/bnf-uk-only."},{"issue":"6","key":"10.1016\/j.ejso.2021.08.024_bib29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/1078155217707335","article-title":"Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer","volume":"24","author":"Kimura","year":"2018","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.ejso.2021.08.024_bib30","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1186\/1471-2407-13-443","article-title":"Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1","volume":"13","author":"Hisashige","year":"2013","journal-title":"BMC Canc"},{"issue":"12","key":"10.1016\/j.ejso.2021.08.024_bib31","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.clinthera.2017.10.017","article-title":"Cost-effectiveness of paclitaxel\u00a0+ ramucirumab combination therapy for advanced gastric cancer progressing after first-line chemotherapy in Japan","volume":"39","author":"Saito","year":"2017","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.ejso.2021.08.024_bib32","unstructured":"Unit costs of health and social care 2015 | PSSRU [internet]. [cited 2019 Sep 6]. Available from: https:\/\/www.pssru.ac.uk\/project-pages\/unit-costs\/unit-costs-2015\/."},{"issue":"10","key":"10.1016\/j.ejso.2021.08.024_bib33","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00277-017-3088-5","article-title":"Blinatumomab in relapsed\/refractory diffuse large B cell lymphoma","volume":"96","author":"Van Dijck","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ejso.2021.08.024_bib34","unstructured":"Exploring the cost of care at the end of life | the Nuffield Trust [Internet]. [cited 2019 Sep 6]. Available from: https:\/\/www.nuffieldtrust.org.uk\/research\/exploring-the-cost-of-care-at-the-end-of-life."},{"issue":"6","key":"10.1016\/j.ejso.2021.08.024_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199553","article-title":"Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer","volume":"13","author":"Peng","year":"2018","journal-title":"PLOS ONE"},{"key":"10.1016\/j.ejso.2021.08.024_bib36","unstructured":"1 Recommendations | Ramucirumab for treating advanced gastric cancer or gastro\u2013oesophageal junction adenocarcinoma previously treated with chemotherapy | Guidance | NICE [Internet]. [cited 2020 Apr 24]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta378\/chapter\/1-Recommendations."},{"key":"10.1016\/j.ejso.2021.08.024_bib37","unstructured":"CYRAMZA (ramucirumab), anticorps monoclonal [Internet]. Haute Autorit\u00e9 de Sant\u00e9. [cited 2020 Apr 24]. Available from: https:\/\/www.has-sante.fr\/jcms\/c_2048967\/fr\/cyramza-ramucirumab-anticorps-monoclonal."},{"key":"10.1016\/j.ejso.2021.08.024_bib38","unstructured":"Nutzenbewertungsverfahren zum wirkstoff ramucirumab - gemeinsamer bundesausschuss [internet]. [cited 2020 Apr 24]. Available from: https:\/\/www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/158\/."},{"issue":"12","key":"10.1016\/j.ejso.2021.08.024_bib39","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","article-title":"Partitioned survival and state transition models for healthcare decision making in oncology: where are we now?","volume":"23","author":"Woods","year":"2020","journal-title":"Value Health"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832100696X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S074879832100696X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:40:17Z","timestamp":1760060417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S074879832100696X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S074879832100696X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2021.08.024","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with gastric cancer and peritoneal metastasis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2021.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}